.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Argus Health
UBS
Accenture
Covington
Dow
Baxter
Farmers Insurance
Fuji

Generated: December 14, 2017

DrugPatentWatch Database Preview

Meda Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for MEDA PHARMS, and what generic alternatives to MEDA PHARMS drugs are available?

MEDA PHARMS has six approved drugs.

There are two US patents protecting MEDA PHARMS drugs.

There are thirteen patent family members on MEDA PHARMS drugs in nine countries and eight supplementary protection certificates in four countries.

Summary for Meda Pharms

International Patents:13
US Patents:2
Tradenames:6
Ingredients:6
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Meda PharmsREGLAN ODTmetoclopramide hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021793-001Jun 10, 2005DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Meda PharmsREGLAN ODTmetoclopramide hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021793-001Jun 10, 2005DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Meda PharmsSOMA COMPOUND W/ CODEINEaspirin; carisoprodol; codeine phosphateTABLET;ORAL012366-002Jul 11, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Meda PharmsSOMA COMPOUNDaspirin; carisoprodolTABLET;ORAL012365-005Jul 11, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Meda PharmsREGLAN ODTmetoclopramide hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021793-002Jun 10, 2005DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Meda PharmsREGLAN ODTmetoclopramide hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021793-002Jun 10, 2005DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Meda PharmsTHYRO-BLOCKpotassium iodideTABLET;ORAL018307-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Meda PharmsROWASAmesalamineSUPPOSITORY;RECTAL019919-001Dec 18, 1990DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Meda PharmsBUTISOL SODIUMbutabarbital sodiumELIXIR;ORAL085380-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Meda Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Meda PharmsSOMA COMPOUNDaspirin; carisoprodolTABLET;ORAL012365-005Jul 11, 1983► Subscribe► Subscribe
Meda PharmsSOMA COMPOUND W/ CODEINEaspirin; carisoprodol; codeine phosphateTABLET;ORAL012366-002Jul 11, 1983► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Meda Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office2266538► Subscribe
Japan2001524956► Subscribe
Japan2008001726► Subscribe
Japan5072513► Subscribe
Canada2284663► Subscribe
Japan2012162558► Subscribe
World Intellectual Property Organization (WIPO)9846215► Subscribe
Hong Kong1137654► Subscribe
European Patent Office0975336► Subscribe
Denmark2147669► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Meda Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0026France► SubscribePRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C/GB08/020United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
12/008Ireland► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
C/GB12/028United Kingdom► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
C/GB95/010United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
QuintilesIMS
Baxter
Boehringer Ingelheim
Medtronic
Cipla
Accenture
Daiichi Sankyo
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot